Compare Sibanye Stillwater Ltd (SBSW) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sibanye Stillwater Ltd vs 22nd Century Group Inc — how do they compare? Sibanye Stillwater Ltd trades at $10 (market cap $6.88B), while 22nd Century Group Inc trades at $0.8 (market cap $621.67K). The key difference: Sibanye Stillwater Ltd is far larger — about 11067× 22nd Century Group Inc's market cap, and Sibanye Stillwater Ltd pays a 8.17% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sibanye Stillwater Ltd for 51 Days and 22nd Century Group Inc for 32 Days on average.
| SBSW | XXII | |
|---|---|---|
Market Cap | $6.88B | $621.67K |
Volume | 4,474,536 | 45,625 |
Sector | Basic Materials | Consumer Staples |
52-Week High | $21.12 | $483.00 |
52-Week Low | $8.00 | $0.80 |
Typical Hold Time | 51 Days | 32 Days |
Enterprise Value | $7.78B | -$3.69M |
Dividend Yield | 8.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SBSW trades at $10.00, up 3.31% with mixed technical signals showing bearish moving averages but neutral oscillators. Fundamentally, the company shows strong revenue growth to $129.68B in 2025 and improved cash flow, though net income remains negative. Analyst consensus is moderately bullish with a $14.25 price target, supported by recent institutional buying activity and positive coverage of H1 2026 results.
The outlook suggests potential upside based on valuation metrics (P/E 8.12, P/S 0.7) and projected 2026 profitability, but risks include persistent negative earnings, high debt levels, and commodity price sensitivity. Investors should weigh the attractive valuation against operational execution challenges in the mining sector.
22nd Century Group (XXII) trades at $0.89, down 0.94% today, with a bearish technical signal despite oversold RSI readings. The company shows severe financial stress with negative gross margins of -54.6% and net income margin of -76.01%, though valuation metrics appear low with P/S of 0.09 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives and expanded retail distribution for VLN products.
While analyst consensus remains bullish with 75% buy ratings and a $1,240 price target, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock presents high-risk speculation on regulatory adoption of reduced-nicotine standards, requiring careful risk assessment given the company's ongoing losses and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
